1. Minimal residual disease as biomarker for optimal biologic dosing of ARA‐C in patients with acute myeloid leukemia. Issue 2 (24th November 2014) Authors: Maurillo, Luca; Buccisano, Francesco; Piciocchi, Alfonso; Del Principe, Maria Ilaria; Sarlo, Chiara; Di Veroli, Ambra; Panetta, Paola; Irno‐Consalvo, Maria; Nasso, Daniela; Ditto, Concetta; Refrigeri, Marco; De Angelis, Gottardo; Cerretti, Raffaella; Arcese, William; Sconocchia, Giuseppe; Lo‐Coco... Journal: American journal of hematology Issue: Volume 90:Issue 2(2015:Feb.) Page Start: 125 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy. (28th April 2013) Authors: Sarlo, Chiara; Buccisano, Francesco; Maurillo, Luca; Cefalo, Mariagiovanna; Di Caprio, Luigi; Cicconi, Laura; Ditto, Concetta; Ottaviani, Licia; Di Veroli, Ambra; Del Principe, Maria Ilaria; Grasso, Maria Assunta; Nasso, Daniela; De Santis, Giovanna; Amadori, Sergio; Venditti, Adriano Other Names: Cuneo Antonio Academic Editor. Journal: Leukemia research and treatment Issue: Volume 2013(2013) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗